ADIPOQ and fatty liver disease: The binding of adiponectin to AdipoR2 in the liver activates AMP-activated protein kinase (AMPK), which stimulates the phosphorylation of acetyl-CoA carboxylase (ACC) and activates PPAR-α and PPAR-γ signaling pathways, leading to a reduction in hepatic lipogenesis, the enhancement of fatty acid oxidation, and the alleviation of hepatic steatosis.